NEWS

Press Release NeoImmuneTech Appoints Gene Namgoong as Chief Operating Officer

Press Release NeoImmuneTech Received U.S. FDA Clearance of IND Application for Phase 1b/2a Study of Hyleukin-7™ (NT-I7) and KEYTRUDA® (Pembrolizumab) in Relapsed/Refractory Advanced Solid Tumors

Press Release NeoImmuneTech Announces Clinical Collaboration to Evaluate Hyleukin-7™ (NT-I7) in Combination with KEYTRUDA® (pembrolizumab) in Patients with Advanced Solid Tumors

Press Release NeoImmuneTech Announces Formation of Scientific Advisory Board to Support Development of its Immunotherapeutics Portfolio

Press Release NeoImmuneTech Appoints Dr. Samuel Zhang as Chief Business Officer

Press Release NeoImmuneTech Announces that the FDA has Allowed the Center for Cancer Research, National Cancer Institute to Proceed with an Investigational New Drug Application to Initiate a Clinical Trial for Hyleukin-7™ with Vaccines in Elderly Cancer Survivors

Press Release Genexine and NeoImmuneTech Announce Dosing of First Patient in the Combination Trial of Hyleukin-7^TM with Merck’s KEYTRUDA^® in Triple-Negative Breast Cancer

Press Release FDA Grants Orphan Drug Designation Status to NeoImmuneTech’s Hyleukin-7 for Idiopathic CD4+ Lymphocytopenia Treatment

Press Release NeoImmuneTech, Genexine, SNUH and POSTECH researchers Announce Presentations at the American Association for Cancer Research (AACR) Annual Meeting 2019

Press Release NeoImmuneTech Receives Authorization to Proceed from the FDA for IND Application to Evaluate Hyleukin-7^TM in Combination with a PD-L1 Inhibitor in Advanced High-Risk Skin Cancers